Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

BOLT

Bolt Biotherapeutics Inc

Dec 01 • 04:00PM ET

0.8900

Dollar change +0.0370
Percentage change 4.34	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.89	Insider Own	35.73%	Shs Outstand	37.80M	Perf Week	-1.11%
Market Cap	33.79M	Forward P/E	-	EPS next Y	-1.60	Insider Trans	-2.09%	Shs Float	24.55M	Perf Month	-11.00%
Income	-71.29M	PEG	-	EPS next Q	-0.47	Inst Own	32.34%	Short Float / Ratio	6.67% / 13.93	Perf Quarter	-17.59%
Sales	7.20M	P/S	4.69	EPS this Y	26.55%	Inst Trans	-0.18%	Short Interest	1.64M	Perf Half Y	-47.65%
Book/sh	3.38	P/B	0.26	EPS next Y	7.40%	ROA	-33.88%	Target Price	4.83	Perf Year	-39.86%
Cash/sh	3.15	P/C	0.28	EPS next 5Y	-	ROE	-45.02%	52W Range	0.85 - 2.03	Perf YTD	-31.54%
Dividend	-	P/FCF	-	EPS past 5Y	-63.47%	ROI	-48.68%	52W High	-56.16%	Beta	0.71
Dividend %	-	Quick Ratio	6.69	Sales past 5Y	201.89%	Gross Margin	44.37%	52W Low	4.71%	ATR	0.07
Employees	94	Current Ratio	6.69	Sales Q/Q	19.70%	Oper. Margin	-1076.27%	RSI (14)	41.28	Volatility	7.56% 7.22%
Optionable	No	Debt/Eq	0.16	EPS Q/Q	26.11%	Profit Margin	-990.43%	Rel Volume	0.60	Prev Close	0.85
Shortable	Yes	LT Debt/Eq	0.14	Earnings	Nov 09 AMC	Payout	-	Avg Volume	117.56K	Price	0.89
Recom	1.33	SMA20	-6.18%	SMA50	-8.79%	SMA200	-32.57%	Volume	70,645	Change	4.34%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-06-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Mar-02-21	Initiated	SVB Leerink	Outperform	$36
Mar-02-21	Initiated	Stifel	Buy	$40
Mar-02-21	Initiated	Morgan Stanley	Overweight	$45
Mar-02-21	Initiated	Guggenheim	Buy	$42

Nov-09-23 04:05PM	Bolt Biotherapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Nov-07-23 07:00AM	Bolt Biotherapeutics to Present at Stifel 2023 Healthcare Conference (GlobeNewswire)
Oct-24-23 12:30PM	10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis (ACCESSWIRE)
Oct-23-23 10:30AM	Bolt Biotherapeutics Presents Updated Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at ESMO 2023 Congress (GlobeNewswire) -7.80%
Oct-18-23 07:00AM	Bolt Biotherapeutics to Present Data at the Society for Immunotherapy of Cancer's 2023 Annual Meeting (GlobeNewswire)
07:00AM	Loading…
Oct-17-23 07:00AM	Bolt Biotherapeutics Announces First Patient Dosed in Phase 1/2 Study of BDC-3042 in Patients with Advanced Cancers (GlobeNewswire)
Oct-16-23 07:00AM	Bolt Biotherapeutics to Present New Clinical Data from Completed Phase 1/2 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Solid Tumors at the ESMO Congress 2023 (GlobeNewswire) +6.25%
Sep-28-23 07:00AM	Bolt Biotherapeutics Receives Orphan Drug Designation for BDC-1001 for Treatment of Gastric Cancers (GlobeNewswire)
Sep-12-23 08:05AM	Bolt Biotherapeutics Announces Issuance of U.S. Patent Covering Dectin-2-Targeting Agonist Antibodies, Including BDC-3042 (GlobeNewswire)
Sep-05-23 04:15PM	Bolt Biotherapeutics to Participate in September Investor Conferences (GlobeNewswire)
Aug-09-23 06:10AM	Bolt Biotherapeutics Second Quarter 2023 Earnings: Misses Expectations (Simply Wall St.)
Aug-07-23 04:10PM	Bolt Biotherapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Aug-03-23 07:30AM	Bolt Biotherapeutics Initiates Phase 2 Clinical Studies of BDC-1001 in Patients With HER2-Positive Cancer (GlobeNewswire)
Jul-31-23 05:27PM	Bolt Biotherapeutics to Present at BTIG Virtual Biotechnology Conference 2023 (GlobeNewswire)
Jun-13-23 11:22AM	Is Bolt Biotherapeutics (NASDAQ:BOLT) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
08:00AM	Loading…
May-30-23 08:00AM	BioLight announces a joint cooperation agreement with Alexion (AstraZeneca Rare Disease) to explore an innovative technology based on natural tears for the diagnosis of retinal diseases (PR Newswire) -6.56%
May-25-23 05:05PM	Bolt Biotherapeutics Highlights Comprehensive Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at 2023 ASCO Annual Meeting (GlobeNewswire)
May-11-23 04:05PM	Bolt Biotherapeutics Reports First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Apr-26-23 10:00AM	Bolt Biotherapeutics to Present Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Tumors at 2023 ASCO Annual Meeting (GlobeNewswire)
Apr-11-23 07:41AM	Investors in Bolt Biotherapeutics (NASDAQ:BOLT) have unfortunately lost 47% over the last year (Simply Wall St.)
Mar-30-23 01:16PM	Bolt Biotherapeutics Says Phase 1 Data Supports Advancing Into Phase 2 Studies (Benzinga)
Mar-29-23 04:15PM	Bolt Biotherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire)
04:05PM	Bolt Biotherapeutics Announces Positive Topline Data from BDC-1001 Phase 1 Dose-Escalation Trial in HER2-Expressing Tumors, Supporting Advancement to Phase 2 Clinical Studies (GlobeNewswire)
Mar-14-23 04:30PM	Bolt Biotherapeutics to Present Preclinical Data for BDC-3042, a Dectin-2-Targeting Agonistic Antibody, at 2023 AACR Annual Meeting (GlobeNewswire) +7.86%
Feb-28-23 08:00AM	Bolt Biotherapeutics to Present at Cowen 43rd Annual Healthcare Conference (GlobeNewswire)
Feb-01-23 08:00AM	Bolt Biotherapeutics to Present at February Investor Conferences (GlobeNewswire)
Jan-04-23 09:31AM	Here's Why We're Watching Bolt Biotherapeutics' (NASDAQ:BOLT) Cash Burn Situation (Simply Wall St.)
Dec-14-22 04:43PM	Bolt Biotherapeutics Appoints Laura Berner to Board of Directors (GlobeNewswire)
Nov-10-22 04:05PM	Bolt Biotherapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
Nov-07-22 08:00AM	Bolt Biotherapeutics to Present Preclinical Data on BDC-3042, Dectin-2 Targeting Agonistic Antibody, at the SITC Annual Meeting (GlobeNewswire)
07:20AM	Loading…
Nov-02-22 07:20AM	Investors in Bolt Biotherapeutics (NASDAQ:BOLT) have unfortunately lost 89% over the last year (Simply Wall St.)
Nov-01-22 10:01AM	Biohaven Ltd. (BHVN) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
08:00AM	Bolt Biotherapeutics to Present at Stifel 2022 Healthcare Conference (GlobeNewswire)
Sep-09-22 12:08PM	16 Best Penny Stocks to Buy Now (Insider Monkey)
Aug-31-22 07:30AM	Bolt Biotherapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference (GlobeNewswire)
Aug-25-22 12:23PM	Eli Lilly (LLY) Stock Up More Than 15% YTD: What Lies Ahead? (Zacks)
12:02PM	J&J (JNJ) Gets EU Nod for Multiple Myeloma Drug Tecvayli (Zacks)
Aug-10-22 04:05PM	Bolt Biotherapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire) +10.53%
Jul-22-22 08:44AM	Is Bolt Biotherapeutics (NASDAQ:BOLT) In A Good Position To Deliver On Growth Plans? (Simply Wall St.) -5.75%
Jun-10-22 07:21AM	Zacks.com featured highlights include Carriage Services, Pool, The Buckle, Bolt Biotherapeutics and Titan Machinery (Zacks) -6.57%
May-27-22 08:00AM	Bolt Biotherapeutics to Present Ex Vivo Data Characterizing the Myeloid Cell Landscape in Solid Tumors at ASCO 2022 (GlobeNewswire)
May-26-22 06:52AM	The past year for Bolt Biotherapeutics (NASDAQ:BOLT) investors has not been profitable (Simply Wall St.)
May-13-22 08:28AM	The Zacks Analyst Blog Highlights Angion Biomedica, Applied Therapeutics, Bolt Biotherapeutics, Ikena Oncology, and Landos Biopharma (Zacks)
May-12-22 04:05PM	Bolt Biotherapeutics Reports First Quarter 2022 Financial Results and Provides Business Highlights (GlobeNewswire) +5.41%
May-11-22 07:32AM	5 Biotech Stocks Set to Outpace Q1 Earnings Estimates (Zacks) -10.30%
Apr-07-22 08:00AM	Bolt Biotherapeutics to Present at 21st Annual Needham Healthcare Conference (GlobeNewswire)
Mar-30-22 04:05PM	Bolt Biotherapeutics Reports Four Quarter and Full Year 2021 Financial Results and Provides Business Highlights (GlobeNewswire)
Mar-08-22 04:30PM	Bolt Biotherapeutics to Present Updates for Three Preclinical Immuno-Oncology Pipeline Programs at AACR Annual Meeting 2022 (GlobeNewswire)
Feb-12-22 06:30AM	Companies Like Bolt Biotherapeutics (NASDAQ:BOLT) Are In A Position To Invest In Growth (Simply Wall St.)
Feb-02-22 08:00AM	Bolt Biotherapeutics to Participate in Upcoming February Conferences (GlobeNewswire)
Jan-27-22 01:43PM	7 Little-Known Penny Stocks That Could Take Off Any Moment (InvestorPlace) -12.40%
Jan-06-22 08:00AM	Bolt Biotherapeutics Doses First Patient with BDC-1001 in Combination with OPDIVO® (nivolumab) in Ongoing Phase 1/2 Clinical Trial for the Treatment of HER2-Expressing Solid Tumors (GlobeNewswire) -10.95%
Dec-17-21 06:14AM	3 Biotech Stocks That Sank: Are Any a Bad-News Buy? (Motley Fool) +5.32%
Dec-16-21 08:00AM	Bolt Biotherapeutics Appoints Nicole Onetto, M.D., to Board of Directors (GlobeNewswire)
Dec-06-21 04:29PM	Why Bolt Biotherapeutics Stock Crashed Today (Motley Fool) -55.81%
09:23AM	Bolt Biotherapeutics Stock Halves on Mediocre Trial Data (Investing.com)
06:00AM	Bolt Biotherapeutics Reports Interim BDC-1001 Phase 1/2 Data Demonstrating a Safe and Well-tolerated Profile and Emerging Clinical Activity at the ESMO Immuno-Oncology Congress 2021 (GlobeNewswire)
Dec-02-21 06:00AM	Bolt Biotherapeutics to Present Interim Clinical Data on BDC-1001 Phase 1/2 Clinical Trial at ESMO Immuno-Oncology Congress 2021 (GlobeNewswire)
Nov-19-21 08:00AM	Bolt Biotherapeutics Announces Changes to its Board of Directors (GlobeNewswire)
Nov-12-21 07:00AM	Bolt Biotherapeutics Presents New Preclinical Data on Three Pipeline Programs at Society for Immunotherapy of Cancer (SITC) Annual Meeting (GlobeNewswire)
Nov-09-21 04:05AM	Bolt Biotherapeutics Reports Third Quarter 2021 Financial Results and Provides Business Highlights (GlobeNewswire) -7.42%
Nov-08-21 08:00AM	Bolt Biotherapeutics to Present at Stifel 2021 Virtual Healthcare Conference (GlobeNewswire)
Nov-03-21 08:00AM	89bio Announces Appointment of Kathy LaPorte to its Board of Directors (GlobeNewswire)
Oct-01-21 08:00AM	Bolt Biotherapeutics to Present Updates on Three Pipeline Programs at the 2021 Society for Immunotherapy of Cancer Annual Meeting (SITC) (GlobeNewswire) +5.77%
Sep-08-21 07:30AM	Bolt Biotherapeutics Announces Clinical Collaboration with Bristol Myers Squibb to Study BDC-1001 in Combination with Opdivo® for Treatment of HER2-Expressing Solid Tumors (GlobeNewswire) -6.38%
Sep-02-21 08:00AM	Bolt Biotherapeutics to Participate in Upcoming September Investor Conferences (GlobeNewswire) +5.07%
Aug-27-21 05:55AM	Innovent Biologics, Bolt Join Forces To Develop Anti-Cancer Candidates (Benzinga) +9.71%
Aug-26-21 04:05PM	Bolt Biotherapeutics and Innovent Biologics Announce Collaboration to Develop Three New Oncology Boltbody ISAC Programs (GlobeNewswire)
Aug-16-21 06:26AM	Here's Why We're Not Too Worried About Bolt Biotherapeutics' (NASDAQ:BOLT) Cash Burn Situation (Simply Wall St.)
Aug-12-21 04:05PM	Bolt Biotherapeutics Reports Second Quarter 2021 Financial Results and Provides Business Highlights (GlobeNewswire) +7.89%
Aug-02-21 04:32PM	European Uber Rival Firm Reaches $4.8B Valuation Following Fundraise For Grocery-Delivery Service: Report (Benzinga) +5.11%
Jul-20-21 12:42AM	Bolt Biotherapeutics, Inc. (BOLT): Are Hedge Funds Right About This Stock? (Insider Monkey)
Jun-22-21 08:16PM	Investor Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Securities Fraud Class Action Lawsuit Filed Against Peloton Interactive, Inc. (Newsfile)
08:00PM	SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Peloton Interactive, Inc. of Class Action Lawsuit and Upcoming Deadline - PTON (PR Newswire)
06:20PM	The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of CCIV, PTON and HMPT (ACCESSWIRE)
05:33PM	Peloton Interactive, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm (GlobeNewswire)
03:41PM	SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Peloton Interactive, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 28, 2021 - (PTON) (Newsfile)
02:10PM	PTON, RLX, UI SHAREHOLDERS - ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Class Action Lawsuits Filed on Behalf of Investors, Lead Plaintiff Deadlines Set (ACCESSWIRE)
01:03PM	This AI home gym wants to replace your Peloton (Yahoo Finance Video)
12:30PM	CLASS ACTION UPDATE for PTON, ATER and WPG: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders (ACCESSWIRE)
12:11PM	Peloton Plans Armband Heart-Rate Monitor in Wearables Push (Bloomberg)
12:00PM	PTON Investor Alert: Shareholder Class Action Deadline Approaching (ACCESSWIRE)
11:33AM	SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Peloton Interactive, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 28, 2021 - PTON (Newsfile)
11:24AM	Berger Montague Reminds Investors of Approaching Deadline in Securities Fraud Class Action Against Peloton Interactive, Inc. (PTON); Lead Plaintiff Deadline is June 28, 2021 (Newsfile)
11:00AM	CCIV, PTON & PINS Upcoming Deadlines: Bronstein, Gewirtz & Grossman LLC Reminds Investors of Class Actions and Encourages Investors to Contact the Firm (ACCESSWIRE)
09:24AM	MONDAY DEADLINE ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Peloton Interactive, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm (Newsfile)
08:00AM	Peloton Announces Corporate Wellness Offering (PR Newswire)
05:22AM	PTON LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Peloton Interactive, Inc. (Newsfile)
02:00AM	Komo Plant Based Foods Expands Plant-Based Meal Helpers(TM) Product Line and Announces New U.S. Trading Symbol KOMOF (ACCESSWIRE)
Jun-21-21 10:43PM	SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS PTON, RLX, UI INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits (GlobeNewswire)
08:00PM	ROSEN, LEADING INVESTOR COUNSEL, Reminds Peloton Interactive, Inc. Investors of the Important June 28 Deadline in Securities Class Action Commenced by the Firm PTON (GlobeNewswire)
07:36PM	Peloton Deadline Alert (Newsfile)
05:43PM	PTON ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 28, 2021 in the Class Action Filed on Behalf of Peloton Interactive, Inc. Limited Shareholders (Newsfile)
04:12PM	Deadline Alert: Kessler Topaz Meltzer & Check, LLP Alerts Investors of Lead Plaintiff Deadline in Securities Fraud Class Action Lawsuit Against Peloton Interactive, Inc. (GlobeNewswire)
02:25PM	Lawsuits Filed Against PTON, UI and RLX - Jakubowitz Law Pursues Shareholders Claims (ACCESSWIRE)
01:40PM	INVESTOR ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Class Action Lawsuits filed on behalf of PTON, RLX, UI Investors, Lead Plaintiff Deadlines Set (ACCESSWIRE)
01:30PM	FINAL DEADLINE NEXT WEEK: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Peloton Interactive, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm (ACCESSWIRE)
11:30AM	CLASS ACTION UPDATE for PTON, PCT and FREQ: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders (ACCESSWIRE)
11:23AM	Deadline Approaching for Peloton Interactive Investors: Berger Montague Reminds Investors of Approaching Deadline in Securities Fraud Class Action Against Peloton Interactive, Inc. (PTON); Lead Plaintiff Deadline is June 28, 2021 (Newsfile)
11:00AM	CCIV, PTON & PINS Upcoming Deadlines: Bronstein, Gewirtz & Grossman LLC Reminds Investors of Class Actions and Encourages Investors to Contact the Firm (ACCESSWIRE)

Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. Its pipeline includes BDC-1001, a HER2-targeting Boltbody Immune-Stimulating Antibody Conjugate (ISAC), BDC-3042, a myeloid-modulating antibody, and multiple Boltbody ISAC collaboration programs. The company was founded by Edgar G. Engleman on January 22, 2015 and is headquartered in Redwood City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ENGLEMAN EDGAR	Director	Nov 30	Sale	0.86	123,079	105,614	251,522	Dec 01 12:31 PM
ENGLEMAN EDGAR	Director	Nov 29	Sale	0.91	25,805	23,379	266,456	Dec 01 12:31 PM
Vivo Capital VIII, LLC	10% Owner	Nov 21	Sale	0.90	3,400	3,060	111,662	Nov 22 06:51 PM
ENGLEMAN EDGAR	Director	Nov 21	Sale	0.90	1,943	1,751	269,587	Nov 22 07:45 PM
Vivo Capital VIII, LLC	10% Owner	Nov 20	Sale	0.92	54,700	50,324	113,119	Nov 20 09:09 PM
ENGLEMAN EDGAR	Director	Nov 20	Sale	0.92	31,257	28,756	269,823	Nov 20 09:31 PM
Vivo Capital VIII, LLC	10% Owner	Nov 17	Sale	0.93	16,354	15,209	136,562	Nov 20 09:09 PM
ENGLEMAN EDGAR	Director	Nov 17	Sale	0.93	9,345	8,691	273,615	Nov 20 09:31 PM
Vivo Capital VIII, LLC	10% Owner	Nov 16	Sale	0.96	15,000	14,400	143,571	Nov 20 09:09 PM
ENGLEMAN EDGAR	Director	Nov 16	Sale	0.96	8,571	8,228	274,749	Nov 20 09:31 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BOLT

Bolt Biotherapeutics Inc

Upgrade your FINVIZ experience